The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Apolipoprotein E 4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging
Open accessAbstract
BACKGROUND: Apolipoprotein E (ApoE) epsilon4 genotype is a well-established risk factor for Alzheimer's disease (AD). However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear. METHODS: We used a nested case-control design from the population-based Canadian Study of Health and Aging (CSHA) to examine the effect of ApoE epsilon4 genotype on the conversion of subjects from normal to CIND and from CIND to AD. We also contrasted these findings with incident cases of AD and vascular dementia (VaD) in the CSHA cohort. RESULTS: The ApoE epsilon4 genotype was a significant risk factor for conversion from CIND to AD and from normal to AD and VaD. However, it was not a significant risk factor for conversion from normal to CIND. This effect is robust to adjustment for age, sex and education level. There is significant interaction between the ApoE epsilon4 genotype and age for AD and for conversion from CIND to AD. No interaction between ApoE epsilon4 genotype, sex, age, ethnicity and education level was found in other subgroup analyses. The positive predictive value of ApoE epsilon4 for predicting CIND conversion to AD was 0.48, and the negative predictive value was 0.65. INTERPRETATION: Possession of an ApoE epsilon4 allele increases the risk of AD developing from CIND. It is also associated with a decrease in the age at onset of AD. Its predictive values do not support its utility as a diagnostic test for predicting progression from CIND to AD, but it may be useful in research studies to enrich study samples that have a higher rate of progression to AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
ApoE-4 and Age at Onset of Alzheimer's Disease: The NIMH Genetics Initiative
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C. P., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.139 · Cited by 479 · cited 1×
“In addition, the ε4 allele appears to exert maximal effect in patients in whom AD is diagnosed between the ages of 55 and 75.(8,9) The ApoE ε4 allele also has been implicated as a risk factor for vascular dementia (VaD), but the findings have been inconsistent, with some studies showing positive association and others…”
ResultMyers, R. H., Schaefer, E. J., Wilson, P. W. F., D'Agostino, R., Ordovas, J. M., Espino, A., Au, R., White, R. F., Knoefel, J. E., Cobb, J. L., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.673 · Cited by 346
Cited by
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Post-stroke dementia – a comprehensive review
Mijajlović, M. D., Pavlović, A., Brainin, M., Heiss, W.-D., Quinn, T. J., Ihle-Hansen, H. B., Hermann, D. M., Assayag, E. B., Richard, E., Thiel, A., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0779-7 · Cited by 693
Mild cognitive impairment: Disparity of incidence and prevalence estimates
Ward, A., Arrighi, H. M., Michels, S., & Cedarbaum, J. M. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.01.002 · Cited by 569
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics
Shaw, L. M., Korecka, M., Clark, C. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2176 · Cited by 339
Cholesterol in Alzheimer's disease
Shobab, L. A., Hsiung, G.-Y. R., & Feldman, H. H. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70248-9 · Cited by 336
Self-citationFeldman, H. H., Ferris, S., Winblad, B., Sfikas, N., Mancione, L., He, Y., Tekin, S., Burns, A., Cummings, J., del Ser, T., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70109-6 · Cited by 335
Diabetes mellitus and dementia
Pasquier, F., Boulogne, A., Leys, D., & Fontaine, P. (2006) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70298-7 · Cited by 276
Post‐stroke cognitive decline: an update and perspectives for clinical research
Brainin, M., Tuomilehto, J., Heiss, W. ‐., Bornstein, N. M., Bath, P. M. W., Teuschl, Y., Richard, E., Guekht, A., Quinn, T., & the Post Stroke Cognition Study Group (2015) · European Journal of Neurology · doi:10.1111/ene.12626 · Cited by 253
Cardiovascular Risk Factors and Incident Alzheimer Disease: A Systematic Review of the Literature
Purnell, C., Gao, S., Callahan, C. M., & Hendrie, H. C. (2009) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318187541c · Cited by 189
Transitions to mild cognitive impairments, dementia, and death: findings from the Nun Study
Tyas, S. L., Salazar, J. C., Snowdon, D. A., Desrosiers, M. F., Riley, K. P., Mendiondo, M. S., & Kryscio, R. J. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm085 · Cited by 163
Predictive value of APOE- 4 allele for progression from MCI to AD-type dementia: a meta-analysis
Elias-Sonnenschein, L. S., Viechtbauer, W., Ramakers, I. H. G. B., Verhey, F. R. J., & Visser, P. J. (2011) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2010.231555 · Cited by 154
Alzheimer’s disease, cerebrovascular disease, and the β-amyloid cascade
Honjo, K., Black, S. E., & Verhoeff, N. P. L. G. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100015547 · Cited by 152
Reduced cerebral glucose metabolism in patients at risk for Alzheimer's disease
Hunt, A., Schönknecht, P., Henze, M., Seidl, U., Haberkorn, U., & Schröder, J. (2007) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2006.12.003 · Cited by 146
Perkisas, S., & Vandewoude, M. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2743 · Cited by 120
EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimerʼns disease
Tai, L. M., Balu, D., Avila-Munoz, E., Abdullah, L., Thomas, R., Collins, N., Valencia-Olvera, A. C., & LaDu, M. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076315 · Cited by 93
MicroRNAs targeting Nicastrin regulate Aβ production and are affected by target site polymorphisms
Delay, C., Dorval, V., Fok, A., Grenier-Boley, B., Lambert, J.-C., Hsiung, G.-Y., & Hébert, S. S. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00067 · Cited by 28
“Details of each cohort have been published elsewhere Frontiers in Molecular Neuroscience www.frontiersin.org July 2014 | Volume 7 | Article 67 | 1 (Anonymous, 1994; Feldman et al., 2003; Hsiung et al., 2004).”
Self-citationWang, Z., Dai, Z., Shu, H., Liu, D., Guo, Q., He, Y., & Zhang, Z. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160724 · Cited by 26
Use of Genetic Variation as Biomarkers for Alzheimer's Disease
Reitz, C., & Mayeux, R. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04945.x · Cited by 24
Metadata
- Authors
- Hsiung, G.-Y. R.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2004-10-12
- Volume
- 171
- Issue
- 8
- Pages
- 863-867
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W1969359388
- Cited by
- 164
- References
- 5
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.